VEGFA and neoplasm: The reduction of VEGF and IL-17A levels in the tumor tissue of the 86 patients in the combined treatment group was paralleled by an increase in the percentage of peripheral blood central memory T cells, activated CD62L+ cytotoxic T cells and the expansion of activated myeloid-derived DCs expressing CD83 and CD80, activating the immune system; this result was ascribed as partly related to the rhythmic method of chemotherapy administration and partly to the maintenance dosing of bevacizumab (70).